Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Evaluation of the Benefit of the H'Ability Home Device Used in Supervised Self-rehabilitation at Home on the Autonomy of Post-stroke Patients

NCT07202520 · tracked via the Priya Life Science France tracker
Sponsor
H'ability
Phase
Not applicable
Started
2025-12-16
Last updated
2026-09-22

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

IVR : H'Ability HomeControl: paper-based exercise guide

IVR : H'Ability Home: H'Ability Home is a Dtx (Digital therapeutics) designed for the neurological rehabilitation of patients who have suffered a stroke, via a wireless virtual reality headset, with a simplified control interface on a tablet or PC

Control: paper-based exercise guide: self-rehabilitation booklet used in current practice in centers

Study summary

The goal of this clinical investigation is to evaluate the benefit of the H'Ability Home device used in supervised self-rehabilitation at home on the autonomy of post-stroke patients.

Participants will perform their self-rehabilitation exercises at home using a virtual reality headset incorporating H'Ability Home software for 6 weeks during the experimental phase. This phase will be compared to a 6-week control phase at home, with self-rehabilitation exercises presented in a paper format.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Patient Inclusion Criteria: * Stroke diagnosis: first stroke, with no history of stroke, documented in the medical record * Currently in rehabilitation (in a center) (full hospitalization or day hospitalization for at least 3 days/week) for another 2 to 4 weeks. * Planned return home (home self-rehabilitation phase): Patients at the end of their rehabilitation stay and scheduled to return home where the self-rehabilitation phase can take place. * Ability to use virtual reality: Physical and cognitive ability to interact with virtual reality devices, at the discretion of therapists. * Adult: Patients aged 18 years or older. * Informed consent: Voluntary agreement to participate in the study after a full explanation of its terms and conditions. * Member of a social security scheme or eligible beneficiary * Distance between home and center included within the usual perimeter of each site. * Presence of a third-party family caregiver at home who has agreed to ensure the patient's safety during self-rehabilitation sessions with the H'Ability Home device (consent) * Availability of a Wi-Fi network and internet access at the patient's home * Presence of an adequate space at home to perform rehabilitation exercises * Person with low to reasonable sensitivity to motion sickness (MSSQ ≤ 15) Patient non inclusion Criteria: * • Visual disorders incompatible with the use of virtual reality (absence of binocular vision, blindness, conjunctivitis, etc.) at the discretion of the investigator. PS: Visual disorders corrected by wearing a vision correction device are not concerned because glasses or contact lenses can be worn when using an IVR headset. * Major cognitive impairment: Severe cognitive impairment affecting the patient's ability to understand or follow study instructions, or to operate the device independently, at the investigators' discretion. * History of epilepsy: History of epileptic seizures, particularly photosensitive seizures, which may be triggered or aggravated by the use of virtual reality. * Medical instability: presence of unstable or uncontrolled medical conditions that could interfere with active participation in rehabilitation. * Psychiatric illnesses: active psychiatric disorders (e.g., psychosis, unstabilized bipolar disorder) that could disrupt participation and continuity of rehabilitation, at the investigators' discretion. * Wearing implantable medical devices or personal medical devices that could be affected by radio waves (pacemakers, cochlear implants, etc.) * Participation in another clinical study: engagement in another clinical study likely to interfere with the study objectives or outcome assessments * Planned hospitalization during the home self-rehabilitation period * Pregnant, childbirth, or breastfeeding women * Persons deprived of their liberty by a judicial (including guardianship, curatorship, and judicial protection) or administrative decision * Persons receiving psychiatric care or admitted to a health or social care facility for purposes other than research * Persons in an emergency situation unable to express their prior consent Third-party family caregiver Inclusion Criteria: * Adult: Person aged 18 years or older * Informed consent: Voluntary agreement to participate in the study after a full explanation of its terms and conditions. * Member of a social security scheme or entitled person * Patient's family caregiver * Ability to assist the patient in using the device * Ability to ensure the patient's safety when using the device * Agreement to assist and ensure the patient's safety when using the device at home * Agreement to provide feedback on the device by completing self-administered questionnaires (UTAUT) - optional Third-party family caregiver non-inclusion Criteria: * Pregnant, childbirth, or breastfeeding women * Persons deprived of their liberty by a judicial (including guardianship, curatorship, and judicial protection) or administrative decision * Persons receiving psychiatric care or admitted to a health or social care facility for purposes other than research * Persons in an emergency situation unable to express their prior consent

Primary outcome measure(s)

  • To evaluate the impact of the H'Ability Home device on the level of autonomy of post-stroke patients compared to the exercise booklet. — T0 (screening), T1(Baseline), T2(week 6), T3(week 7), T4 (week 13)
    Level of autonomy by the functional independence measure (FIM) score. From 18 (no autonomy) to 126 (full autonomy).

Trial sites (5)

FacilityCityRegionStatus
Fondation Hopale - Centre de Jacques Calvé Berck France Recruiting
Hôpital Léon Bérard Hyères France Recruiting
Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles (CMRRF) de KERPAPE Ploemeur France Recruiting
Pôle Saint Hélier Rennes France Recruiting
Fondation ILDYS - Centre de Perharidy Roscoff France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07202520 on ClinicalTrials.gov ↗ ← All trials in France